Concepedia

Author

Toshie Iijima

Dokkyo Medical UniversityORCID

Also Known As

Jojima Teruo, Site Investigators (duplicates excluded), T Iijima, T. Iijima, TOSHIE IIJIMA, Toshie Iijima

50

Publications

1.3K

Citations

14

H-Index

43

Concepts

All Affiliations

Dokkyo Medical UniversityDokkyo Medical University Saitama Medical CenterFukushima Medical University
TI

About

Toshie Iijima is an author at Dokkyo Medical University specializing in medicine, diabetes, and metabolic syndrome.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

11

11

458

2

Health Sciences

5

5

216

3

Biochemistry

2

2

49

4

Public Health

1

1

25

5

Cell Biology

1

1

101

Toshie Iijima

×

17

Publications

1.2K

Citations

13

H-Index

YearCitations

Evaluation of the effects of dapagliflozin, a sodium‐glucose co‐transporter‐2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Masanori Shimizu, Kunihiro Suzuki, Kanako Kato,

Diabetes Obesity and Metabolism

2018

364

Empagliflozin (an SGLT2 inhibitor), alone or in combination with linagliptin (a DPP-4 inhibitor), prevents steatohepatitis in a novel mouse model of non-alcoholic steatohepatitis and diabetes

Teruo Jojima, Takanori Tomotsune, Toshie Iijima,

Diabetology & Metabolic Syndrome

2016

197

The SGLT2 Inhibitor Canagliflozin Prevents Carcinogenesis in a Mouse Model of Diabetes and Non-Alcoholic Steatohepatitis-Related Hepatocarcinogenesis: Association with SGLT2 Expression in Hepatocellular Carcinoma

Teruo Jojima, Sho Wakamatsu, Masato Kase,

International Journal of Molecular Sciences

2019

120

Liraglutide, a GLP-1 receptor agonist, inhibits vascular smooth muscle cell proliferation by enhancing AMP-activated protein kinase and cell cycle regulation, and delays atherosclerosis in ApoE deficient mice

Teruo Jojima, Kohsuke Uchida, Kazumi Akimoto,

Atherosclerosis

2017

101

Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase‐4 in patients with type 2 diabetes and non‐alcoholic fatty liver disease

Yoshimasa Aso, Kanako Kato, Shintaro Sakurai,

International Journal of Clinical Practice

2019

97

Sitagliptin, a DPP-4 inhibitor, alters the subsets of circulating CD4+ T cells in patients with type 2 diabetes

Yoshimasa Aso, Maiko Fukushima, Masaaki Sagara,

Diabetes Research and Clinical Practice

2015

40

Sitagliptin, a dipeptidyl peptidase-4 inhibitor, increases the number of circulating CD34+CXCR4+ cells in patients with type 2 diabetes

Yoshimasa Aso, Teruo Jojima, Toshie Iijima,

Endocrine

2015

34

Empagliflozin decreases the plasma concentration of plasminogen activator inhibitor-1 (PAI-1) in patients with type 2 diabetes: Association with improvement of fibrinolysis

Shintaro Sakurai, Teruo Jojima, Toshie Iijima,

Journal of Diabetes and its Complications

2020

34

Comparative study between high-dose fluvastatin and low-dose fluvastatin and ezetimibe with regard to the effect on endothelial function in diabetic patients

Yoshiaki Kawagoe, Yoshiyuki Hattori, Ayuko Nakano,

Endocrine Journal

2011

25

The serum level of soluble CD26/dipeptidyl peptidase 4 increases in response to acute hyperglycemia after an oral glucose load in healthy subjects: association with high-molecular weight adiponectin and hepatic enzymes

Yoshimasa Aso, Tomoko Terasawa, Kanako Kato,

Translational research

2013

25

Page 1